Sign in
Not yet recruitingPhase 2

SHIELD – Swift Hydrocortisone Intervention after trauma exposure

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Netherlands4 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
196 people, planned
Started
1 Jan 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
13 July 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age: 18 to 65
  • Sex/gender: any
  • Proficiency in Dutch
  • Presented at ED as a result of a one-time incident involving injury as a result of an accident, physical or sexual violence or another kind of exceptional situation

Who cannot take part

  • Psychiatric counterindications assessed through anamnesis
  • Not able to give informed consent
  • Not allowed to take hydrocortisone
  • Practical exclusion criteria (e.g., no reliable access to telephone or internet)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective is to investigate whether hydrocortisone, compared to placebo, leads to lower clinician-assessed PTSD symptomology 3 months after trauma.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Fit questions
Built from 2025-523350-13-02, who can take part
Record updated
13 July 2026